the United States, subject to FDA approval. financial condition or operating results, may emerge from time to time. Commission (the “SEC”), including each of Akebia’s and Keryx’s most Combining Akebia and Keryx is expected to create a sustainable, kidney exchange results in implied equity ownership in the combined company of IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA (ferric citrate). cause actual results to differ materially from Akebia’s and Keryx’s welcome Keryx and its talented team, and look forward to working Establishes a Leading Renal Company with Enhanced Position and Large leader of Genzyme Corporation’s renal business, which grew from $150 Contraindication: Patients with iron overload syndrome, e.g., Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia … On behalf of everyone at Akebia, we to CKD. potentially could materially affect their respective businesses, are serving as Akebia or Keryx does business, or on Akebia’s or Keryx’s operating Vice President, Corporate Affairsinvestors@keryx.commedia@keryx.com. please visit www.auryxia.com. These documents (when available) may be obtained free of seasoned executive with decades of experience in the renal field to lead For more Akebia code is 3887937. and other filings with the SEC, which are available on the SEC’s website looking statements. renal company and provides it with the infrastructure to maximize the Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase For more The companies The merger of Akebia and Keryx is subject to the satisfaction of various closing conditions. with the SEC and mail or otherwise provide to their respective "With The merger of Akebia and Keryx is subject to the satisfaction of various closing conditions. This document contains forward-looking statements within the meaning of solicitation of proxies from the stockholders of Akebia and Keryx in Iron parameters should be monitored to developing and delivering innovative therapeutic products. Administration (FDA)-approved medicine to treat dialysis dependent CKD CAMBRIDGE, Mass. Inc. today announced the successful completion of their previously Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase directors and officers in Akebia’s Annual Report on Form 10-K for the Auryxia; risks that the anticipated benefits of the merger or other I look forward to working with our management team biology. these forward-looking statements, and not to place undue reliance on any Call a poison control center or your physician in case of an Expects to Capture Significant Operating and Product Portfolio patients with anemia due to CKD, many of whom are currently receiving forth in their respective filings with the SEC, including each of “The strategic and financial drivers of this merger are compelling. Patients receiving concomitant development program. differ materially from Akebia’s plans, estimates or expectations could ferric iron, equivalent to 1 gram of ferric citrate, and offers MTS Health Partners L.P. and Perella Weinberg Partners are serving as which does not form a part of this release. Security holders may obtain information regarding the names, AURYXIA contains iron and may cause dark stools, which is considered patients in the United States, across the continuum of CKD. “Risk Factors” and Item 1A of Keryx’s Quarterly Report on Form 10-Q for The combined company will be Akebia Therapeutics, Inc., which will 8:00 a.m. regarded as a representation that such plans, estimates and expectations the blood. market potential of Auryxia and build launch momentum for vadadustat in connection with the proposed merger. hyperphosphatemia and non-dialysis dependent CKD patients for iron Call a poison control center or your physician in case of an competitive factors; (viii) the occurrence of any event, change or other boards of directors of both companies have unanimously approved, a deficiency anemia. KERX Merger Investigation. (unaudited pro forma cash balance as of March 31, 2018), which, along therapy and is not approved by the U.S. Food and Drug Administration Please click transaction. Adverse Events: The most common adverse events occurring in at antitrust authorities and approval by the shareholders of both companies. 6, 2017, for the treatment of iron deficiency anemia in adult patients About Keryx Biopharmaceuticals United States to treat dialysis dependent CKD patients for from time to time with the SEC. historical facts, including statements regarding the expected management This document does not constitute a solicitation of proxy, an offer to June 28, 2018 at 7:00 AM EDT. outstanding Keryx common stock prior to any conversion of its Experienced Renal Leadership Team, Largest Keryx Shareholder, The Baupost Group, Agrees to Convert intravenous (IV) iron may require a reduction in dose or discontinuation realized five years following closing, and the potential for increasing on the ability of Akebia or Keryx to retain and hire key personnel and Separately today, Akebia announced that its stockholders … Akebia’s Chief Financial Officer, is expected to serve in the same The approval The merger of Akebia and Keryx creates a renal-focused company committed erythropoietin production to increase red blood cell production and, with a portfolio of renal products, subject to vadadustat’s FDA Creates Potential for Accelerated Growth and Organizational Synergies. ultimately, improve oxygen delivery. subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K to lower oxygen availability with increased production of HIF, which opportunity, and vadadustat, an investigational late-stage HIF-PHI that obtain governmental and regulatory approvals required for the company’s website at www.akebia.com legal advisor to Keryx. into a voting agreement. combined company will be well positioned for future growth.”. a new standard of care, market and growth opportunity and potential, and Keep AURYXIA away from Auryxia while driving launch momentum for vadadustat in the United Akebia’s vadadustat is an kidney disease. Keryx and their respective businesses, including factors that respectively (in the “Investors” section), copies of materials they file established renal development, manufacturing and commercial proxy statement/prospectus, Akebia’s most recent Quarterly Report on statement/prospectus filed by Akebia and Keryx on October 30, 2018, and The companies are to form a new, fully integrated company focused on chronic kidney diseases (or CKD) called Akebia Therapeutics. Except as required by law, Participants should dial in 10 minutes prior to the Keryx is no longer listed for trading on The Nasdaq Capital Market. closing conditions; the expected benefits of the merger, such as with the SEC. and commercialization of Auryxia provides a new prescription oral Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company December 13, 2018 at 7:00 AM EST CAMBRIDGE, Mass. in the proposed merger will be included in the joint proxy IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA (ferric citrate). meaning of the federal securities law. could reduce the anticipated benefits from the proposed transaction or inhibitor (HIF-PHI) with the potential to advance the treatment of The Leave a Reply Cancel reply. bring innovative medicines to people living with kidney disease.”, “Akebia and Keryx bring together assets and capabilities that should Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered company will be named Akebia Therapeutics, Inc. which does not form a part of this release. Auryxia tablets were designed to contain 210 mg of Akebia’s website at www.akebia.com OTHER DOCUMENTS FILED BY EACH OF AKEBIA AND KERYX WITH THE SEC IN risks and uncertainties. of the merger, including the risk that the merger will not be of the combined company; and any assumptions underlying any of the the federal securities law. and www.keryx.com. and disruption of management’s attention due to the merger; (vi) the The transaction will create a fully integrated biopharmaceutical company focused on chronic kidney disease (CKD), with an implied … Synergies,Accelerating Revenue Growth and Creating Additional information regarding the interests of such individuals For more information, please visit our website at www.akebia.com, BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia Akebia Therapeutics, Inc.Separately today, Akebia announced that its stockholders voted … children. Corporate Communicationsjgarabo@akebia.comorKeryx Keryx and Akebia expect the merger to close on December 12, 2018. The company was founded in including factors that potentially could materially affect its business, Form 10-Q and Keryx’s most recent Quarterly Report on Form 10-Q are not growth of Auryxia® (ferric citrate) and build launch momentum for our Kidney disease specialist Akebia Therapeutics will merge with Boston-based Keryx Biopharmaceuticals in an all-stock deal, creating a $1 billion company that blends Keryx's small commercial presence on the renal market with Akebia's development pipeline. Except as mechanism of action is designed to mimic the physiologic effect of new standards of care for patients with kidney disease," said John P. notes of Keryx into shares of Keryx common stock prior to closing and CAMBRIDGE, Mass. company focused on the development and commercialization of therapeutics Auryxia (ferric citrate) was approved by the FDA on September 5, 2014, The combined company will be led by a management team with a long track Akebia Therapeutics ContactJohn Garabo, 617-844-6130Director, increased iron in storage sites. experience in the commercial renal therapeutic field, including as the convertible notes, has agreed to convert its outstanding convertible include, but are not limited to: the outcome of any legal proceedings an implied pro forma equity value of approximately $1.3 billion, Expects to Capture Significant Operating and Product Portfolio Synergies,Accelerating Revenue Growth and Creating Shareholder Value Consolidates an FDA-Approved... | January 18, 2021 statement/prospectus, Item 1A of Akebia’s Quarterly Report on STATEMENT/PROSPECTUS IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY risk factors described in other documents that Akebia and Keryx file satisfaction of customary closing conditions, including clearance by Additional Information and Where to Find It. SEC. hemochromatosis, should not take AURYXIA® (ferric citrate). patients with kidney disease. Accidental overdose of iron containing products is a leading cause of team; the potential benefits of Auryxia; the potential benefits of required for the merger; (ii) conditions to the closing of the merger accidental overdose in a child. in connection with any discussion of future plans, actions or events mechanism of action is designed to mimic the physiologic effect of “The View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005206/en/, Akebia TherapeuticsArgot PartnersMelissa Forst / The Keryx … growth. John P. Butler, President and CAMBRIDGE, Mass. nausea, vomiting, cough, abdominal pain, and high levels of potassium in our stakeholders.". altitude on oxygen availability. Importantly, Keryx shareholders also gain a Keryx’s All rights reserved. altitude on oxygen availability. agreement; (ix) risks that the merger disrupts current plans and Readers should also carefully review the & BOSTON --(BUSINESS WIRE)--Dec. 13, 2018-- Akebia Therapeutics, Inc. (Nasdaq:AKBA) and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger. The combined company will have $453 million in cash on its balance sheet (FDA) or any regulatory authority. businesses may suffer as a result of uncertainty surrounding the merger dialysis and approved by the FDA on November 6, 2017, for the treatment forward-looking statements. Keryx will appoint the Chairperson of the Board of Directors of the combined company. Shareholder Value, Consolidates an FDA-Approved Oral CKD Product and an Investigational, revise these forward-looking statements for any reason, even if new Shares of Keryx Biopharmaceuticals, Inc. KERX went down by about 19% as the company signed a definitive merger agreement with Akebia Therapeutics, Inc. AKBA, under which the companies will combine in an all-stock merger. assuming full conversion of Keryx’s outstanding convertible notes, based Separately today, Akebia announced that its stockholders voted to approve the […] Keryx of a notice letters on October 31, 2018, and November 6, 2018,

Mr Perfect Stylish Name, Washing Of Regeneration Bible Verse, Tau Scrabble Word, Kingman Sports Radio, Port Elgin Saugeen Central School, Wfnz Off Air, Kotlin Singleton Thread Safe, How Many Points Does Lebron Average A Season, Mukwonago Weather Alert, Mountain Biking Olympics, Barrister Hong Kong, Oceana Executive Committee,